AU2012296905B2 - Combination therapy with an anti - CD19 antibody and a purine analog - Google Patents

Combination therapy with an anti - CD19 antibody and a purine analog Download PDF

Info

Publication number
AU2012296905B2
AU2012296905B2 AU2012296905A AU2012296905A AU2012296905B2 AU 2012296905 B2 AU2012296905 B2 AU 2012296905B2 AU 2012296905 A AU2012296905 A AU 2012296905A AU 2012296905 A AU2012296905 A AU 2012296905A AU 2012296905 B2 AU2012296905 B2 AU 2012296905B2
Authority
AU
Australia
Prior art keywords
lymphoma
seq
sequence
region
fludarabine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012296905A
Other languages
English (en)
Other versions
AU2012296905A1 (en
Inventor
Jutta AMERSDORFFER
Susanne KROHN
Lisa Rojkjaer
Stefan Steidl
Mark Winderlich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AU2012296905A1 publication Critical patent/AU2012296905A1/en
Application granted granted Critical
Publication of AU2012296905B2 publication Critical patent/AU2012296905B2/en
Assigned to INCYTE CORPORATION reassignment INCYTE CORPORATION Request for Assignment Assignors: MORPHOSYS AG
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2012296905A 2011-08-16 2012-08-14 Combination therapy with an anti - CD19 antibody and a purine analog Active AU2012296905B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161523862P 2011-08-16 2011-08-16
EP11177660.5 2011-08-16
US61/523,862 2011-08-16
EP11177660 2011-08-16
PCT/EP2012/065904 WO2013024095A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a purine analog

Publications (2)

Publication Number Publication Date
AU2012296905A1 AU2012296905A1 (en) 2013-12-05
AU2012296905B2 true AU2012296905B2 (en) 2017-01-05

Family

ID=47714800

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012296905A Active AU2012296905B2 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - CD19 antibody and a purine analog

Country Status (25)

Country Link
US (3) US20140227277A1 (enExample)
EP (2) EP2744826B1 (enExample)
JP (1) JP6114273B2 (enExample)
KR (3) KR20140071368A (enExample)
CN (1) CN103703027B (enExample)
AU (1) AU2012296905B2 (enExample)
BR (1) BR112013033916B1 (enExample)
CA (1) CA2841738C (enExample)
CY (1) CY1125148T1 (enExample)
DK (1) DK2744826T3 (enExample)
ES (1) ES2909720T3 (enExample)
HR (1) HRP20220224T1 (enExample)
HU (1) HUE058855T2 (enExample)
IL (1) IL230295B (enExample)
LT (1) LT2744826T (enExample)
MX (1) MX353589B (enExample)
PL (1) PL2744826T3 (enExample)
PT (1) PT2744826T (enExample)
RS (1) RS63121B1 (enExample)
RU (1) RU2664462C9 (enExample)
SG (1) SG10201606788VA (enExample)
SI (1) SI2744826T1 (enExample)
SM (1) SMT202200160T1 (enExample)
WO (1) WO2013024095A1 (enExample)
ZA (1) ZA201401835B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
ES2523901B1 (es) * 2013-05-31 2015-12-02 Universidad Autónoma de Madrid Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica
IL249533A0 (en) * 2014-06-16 2017-02-28 Xencor Inc Treatment of chronic lymphocytic leukemia
US20170137516A1 (en) * 2014-06-16 2017-05-18 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
SMT201900647T1 (it) 2015-05-26 2020-01-14 Morphosys Ag Combinazione di un anticorpo anti-cd19 e un inibitore della tirosina chinasi di bruton e suoi usi
WO2017032679A1 (en) * 2015-08-21 2017-03-02 Morphosys Ag Combinations and uses thereof
LT3916392T (lt) * 2016-05-30 2024-08-26 Incyte Corporation Pacientų gydymo anti-cd19 terapinės naudos prognozavimo būdai
AU2017348624B2 (en) 2016-10-28 2024-09-26 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
BR112019025034A2 (pt) 2017-05-31 2020-06-30 Morphosys Ag combinação
JP7279011B2 (ja) 2017-07-10 2023-05-22 インターナショナル－ドラッグ－ディベロップメント－バイオテック 抗ｃｄ２０抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗ｃｄ１９抗体を用いるｂ細胞悪性の治療
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments
US20230357392A1 (en) * 2021-12-22 2023-11-09 Morphosys Ag Treatment Paradigm for an Anti-CD19 Antibody Therapy
WO2025012080A1 (en) 2023-07-13 2025-01-16 Christian-Albrechts-Universität Zu Kiel Humanized anti-cd7 antibody

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11852A (en) 1854-10-31 Abraham bassford
US106A (en) 1915-08-24 Specipication
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
HK1041221A1 (zh) * 1998-08-11 2002-07-05 Idec药物公司 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法
HK1046635B (en) * 1999-06-09 2009-10-09 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
WO2002022212A2 (en) 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
JP5215180B2 (ja) 2005-06-20 2013-06-19 メダレックス インコーポレーティッド Ｃｄ１９抗体およびその使用法
WO2007064911A1 (en) * 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
ATE509954T1 (de) * 2005-12-30 2011-06-15 Merck Patent Gmbh Anti-cd19-antikörper mit reduzierter immunogenität
ES2402591T3 (es) * 2006-08-14 2013-05-07 Xencor Inc. Anticuerpos optimizados que seleccionan como diana CD19
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
ES2659517T3 (es) * 2007-05-30 2018-03-16 Xencor, Inc. Métodos y composiciones para inhibir células que expresan CD32B
SI2211904T1 (sl) 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
AU2010263272C1 (en) 2009-06-24 2016-02-11 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
RU2012109451A (ru) * 2009-08-14 2013-09-27 Роше Гликарт Аг Комбинированная терапия на основе афукозилированного антитела к cd20 в сочетании с флударабином и/или митоксантроном
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
CN102711479A (zh) * 2009-11-06 2012-10-03 无限药品股份有限公司 Hedgehog通道抑制剂的口服制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOCHENDERFER J. et al, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood, 2010, Vol. 116(20), pp 4099-4102 *

Also Published As

Publication number Publication date
IL230295B (en) 2018-03-29
BR112013033916B1 (pt) 2022-11-16
PL2744826T3 (pl) 2022-05-30
ES2909720T3 (es) 2022-05-10
SMT202200160T1 (it) 2022-05-12
WO2013024095A1 (en) 2013-02-21
US20140227277A1 (en) 2014-08-14
RU2664462C9 (ru) 2018-09-28
NZ617771A (en) 2016-01-29
RU2664462C2 (ru) 2018-08-17
RU2014103490A (ru) 2015-09-27
KR102117202B1 (ko) 2020-06-01
HRP20220224T1 (hr) 2022-04-29
JP6114273B2 (ja) 2017-04-12
EP2744826A1 (en) 2014-06-25
KR20140071368A (ko) 2014-06-11
CA2841738A1 (en) 2013-02-21
LT2744826T (lt) 2022-04-25
EP4083071A3 (en) 2023-02-22
KR20200060779A (ko) 2020-06-01
JP2014525925A (ja) 2014-10-02
CA2841738C (en) 2022-12-06
MX2013014935A (es) 2014-07-09
SG10201606788VA (en) 2016-09-29
DK2744826T3 (da) 2022-03-28
MX353589B (es) 2018-01-19
RS63121B1 (sr) 2022-05-31
ZA201401835B (en) 2015-06-24
KR20190094478A (ko) 2019-08-13
PT2744826T (pt) 2022-05-19
HUE058855T2 (hu) 2022-09-28
CY1125148T1 (el) 2024-12-13
US20240424012A1 (en) 2024-12-26
EP2744826B1 (en) 2022-02-09
EP4083071A2 (en) 2022-11-02
US20200352975A1 (en) 2020-11-12
CN103703027B (zh) 2018-01-12
SI2744826T1 (sl) 2022-05-31
CN103703027A (zh) 2014-04-02
BR112013033916A2 (pt) 2017-11-28

Similar Documents

Publication Publication Date Title
US20240424012A1 (en) Combinations and uses thereof
US20240009196A1 (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
US12194095B2 (en) Combinations and uses thereof
AU2012296905A1 (en) Combination therapy with an anti - CD19 antibody and a purine analog
AU2012296907B2 (en) Combination therapy with an anti - CD19 antibody and a nitrogen mustard
JP2014525925A5 (enExample)
AU2012296907A1 (en) Combination therapy with an anti - CD19 antibody and a nitrogen mustard
HK40081594A (en) Combination therapy with an anti-cd19 antibody and a nitrogen mustard
HK40069168A (en) Combinations and uses thereof
NZ617771B2 (en) Combination therapy with an anti - cd19 antibody and a purine analog
HK1195322A (en) Combination therapy with an anti-cd19 antibody and a purine analog
HK1195322B (en) Combination therapy with an anti-cd19 antibody and a purine analog

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: INCYTE CORPORATION

Free format text: FORMER OWNER(S): MORPHOSYS AG